Merging CRISPR editing and single cell sequencing technologies to uncover the biology of human neuro development diseases. Exciting talk by Novartis Institute for Bio Medical Research at SMi's London Summit on 3D Cell Culture by Max Salick! http://www.3D-CellCulture.com/i

Exciting market overview provided by West Pharmaceuticals Director of Product Management at SMi's 10th Annual European summit on Pre-Filled Syringes next Jan. Interesting talk on current trends and new tech. http://www.pre-filled-syringes.com/ihub

NorthWest Biotherapeutics Inc. (NWBO) are once again scheduled to present a keynote at the 6th annual Cancer Vaccines industry summit in Central London. Looking forward to hearing CEO Linda Powers present new updates on DCVax® More information on the event is available at http://www.cancervaccinesevent.com/ihub

How profitability is the biosimilar business?

Will be interesting to hear updates on how the Teva business case will change when the Strategic Associate to the Generics President & CEO presents on the biosimilars business case this September in London.

Details on Biosimilars & Biobetters 2017 can be found at http://www.biosimilars-europe.com/inhu

A new update on DCVax by CEO Linda Powers in London this Sept!
Will be interesting to see what future plans are for the vaccine. More information on the talk at Cancer Vaccines 2017 can be found at http://www.cancervaccinesevent.com/ihub

Boeing set to exhibit at the UK's Global Milsatcom show this November! Also presenting, will be interesting to see what they speaking about with regards to satellite comms! Event website

AstraZeneca Head of Neuroscience, Dr Iain Chessell, presents new opportunity to expand efficacy of anti-NGF's to neuropathic pain. Interesting to see what they have in store at the 17th Pain Therapeutics industry summit. insert-text-here

A new path to pain relief. Time for change with a peripherally acting Kappa Opioid Receptor Against (KORA)! Cara's chief medical officer Dr Joseph Stauffer presents clinical trial data for CR845 in the treatment of acute and chronic pain this May at the 17th annual industry summit on Pain Therapeutics. http://www.pain-therapeutics.co.uk/ihub

New updates on NKTR-181 - the novel opioid for chronic pain, presented by Stephen Doberstein , Senior Vice President and Chief Scientific Officer from Nektar Therapeutics. More information on the talk at the 17th Annual Pain Therapeutics summit in London are available at http://www.pain-therapeutics.co.uk/ihub

New talk on human drug development by veterinary trials for novel pain therapies BY Steven Kamerling, Therapeutic Area Head for Pain, Inflammation and Oncology at Zoetis. Details on the talk this May at Pain Therapeutics 2017 are available at http://www.pain-therapeutics.co.uk/ihub

Joseph Stauffer, Chief Medical Officer from Cara Therapeutics, Inc. will be presenting in London at the 17th Annual Pain Therapeutics conference this May.

His talk entitled "A NEW PATH TO PAIN RELIEF: TIME FOR CHANGE WITH A PERIPHERALLY ACTING KAPPA OPIOID RECEPTOR AGONIST (KORA)" will include new results from clinical trial data for CR845 in the treatment of acute and chronic pain.

Details available at http://www.pain-therapeutics.co.uk/ihub

Smithers Rapra have forecast the global market for Pre-Filled Syringes to rise to $6.6 Billion by 2020. Good news for Sanofi!

Excited to hear more insight from the Senior Director of their PFS platform - Paolo Mangiagalli, when he presents in Central London at Pre-Filled Syringes Europe.

Details on the event in Jan 2017 are available at http://www.pre-filled-syringes.com/ihub

Smithers Rapra have forecast the global market for Pre-Filled Syringes to rise to $6.6 Billion by 2020. Good news for GSK!

Excited to hear more insight from their Device Development Manager - David Blakey, when he presents in Central London at Pre-Filled Syringes Europe.

Details on the event in Jan 2017 are available at http://www.pre-filled-syringes.com/ihub

Smithers Rapra have forecast the global market for Pre-Filled Syringes to rise to $6.6 Billion by 2020. Good news for West!

Excited to hear more insight from their Director of Global Product Management in Pre-filled Systems and Delivery - Christa Jansen-Otten, when she presents in Central London at Pre-Filled Syringes Europe.

Details on the event in Jan 2017 are available at http://www.pre-filled-syringes.com/ihub

Just over 1 week to go until Linda Powers CEO presents new updates on DCVax at SMi's Cancer Vaccines show on 21st & 22nd Sept in London, UK. www,cancervaccinesevent.com

Dr Mahesh Kumar, VP of Global Biological Research & Development at Zoetis will be presenting an interesting keynote address entitled "First to know and fast to market!" at the Superbugs USA congress. Details are available at http://www.superbugs-usa.com/ihub

Linda Powers, CEO from Northwest Biotherapeutics will be providing new updates in 4 weeks in London at Cancer Vaccines 2016. Details available at http://www.cancervaccinesevent.com/ihub

New interview released with Daejin Abidoye, Medical Director from Roche-Genentech in the run up to his keynote address at Cancer Vaccines 2016 next month.

"As a Medical Director in Clinical Development, I help oversee the Genitourinary (GU) Malignancies program for our Immuno-Oncology Franchise. Our lead molecule, Atezolizumab, is a humanized engineered monoclonal antibody that selectively targets PD-L1 and has shown clinical activity in various solid tumor malignancies. As the Clinical Lead for Atezolizumab in Urothelial Cancer, I have led the clinical team through the growth of a comprehensive product development program in urothelial cancer, to the recent approval of atezolizumab for metastatic urothelial cancer (mUC) in the United States."

The full interview is available at http://www.smi-online.co.uk/goto/2016cancervaccinesevent.asp#tab_downloads

Development of strategies to address primary resistance and treatment failure in cancer therapy showcased by MSD next month at Cancer Vaccines 2016 in a keynote by Senior VP and Head, Global Clinical Development, Roy Baynes. http://www.cancervaccinesevent.com/ihub

Following on from the 2015 show, CEO Linda Powers gives the latest update on DCVax® at Cancer Vaccines 2016 with new insight into dose manufacturing. http://www.cancervaccinesevent.com/ihub

Principle for Global Generics and Biosimilars, Alan Sheppard, to give a keynote on Biosimilar trends at 7th annual European congress. http://www.biosimilars-europe.com/ihub

Merck Group give case study insight into emerging biosimilar asset class - strategy and portfolio management at 7th annual Biosimilars Europe conference this Sept. Details available at http://www.biosimilars-europe.com/ihub

CEO Linda Powers scheduled to present at Cancer Vaccines Sept 21st & 22nd in London. http://www.cancervaccinesevent.com/ihub

Her keynote entitled 'DCVAX®: NOVEL PERSONALISED IMMUNE THERAPIES FOR SOLID TUMOURS,' will include discussions on how:

• DCVax® is a fully personalised precision medicine, tailored to the individual patient and their tumour
• DCVax® mobilizes many active agents of the immune system to hit many targets on the cancer, unlike conventional cancer drugs and some other immune therapies, which generally use a single active agent to hit a single target on the cancer
• Full course of DCVax® doses can be manufactured in a single batch within about a week, and can be stored frozen until needed (including for years).

Nestle research centre will be providing interesting updates on nutritional approaches for the primary prevention of allergic diseases with evidence and insight into on-going research. Details on the allergies meeting are available at http://www.allergies-event.com

Danone Nutricia Research will be presenting new updates on the discovery and validation of biomarkers in allergies for use in dietary intervention studies. A great outlook into future developments. Details on the allergies meeting are available at http://www.allergies-event.com

CEO Linda Powers will be presenting new updates on DCVAX® at Cancer Vaccines in London this September. http://www.cancervaccinesevent.com

Strategy on opioid abuse
Stephen Doberstein Senior Vice President and Chief Scientific Officer from Nektar Therapeutics will be chairing the 16th annual Pain Therapeutics conference in May! Engineering brain entry rate to reduce opioid abuse indicating that Nektar are on the cusp of some major developments in Pain drugs. Pain Therapeutics

Northrop Grumman’s Vice President of Communication Systems will speak next week about the affordable protected Satcom solutions for coalition partners at Global MilSatCom 2015, the largest Satellite event taking place in Europe! https://www.smi-online.co.uk/defence/uk/global-milsatcom

Lockheed Martin Space Systems will give an interesting presentation on MILSATCOM innovation next week at Europe’s largest Satellite event, Global MilSatCom 2015. They will also participate in a panel discussion about the current and future trends of satellite technology alongside Inmarsat Global Government, Intelsat, LuxGovSat and Airbus Defence and Space! https://www.smi-online.co.uk/defence/uk/global-milsatcom

Intelsat are one of the sponsors for Global MilSatCom 2015, Europe’s largest Satellite event taking place next week. Their Vice President of Satellite Networks and Space Services will be participating in an anticipated panel discussion about the current and future trends of satellite technology alongside Inmarsat Global Government, Lockheed Martin Space Systems, LuxGovSat and Airbus Defence and Space! https://www.smi-online.co.uk/defence/uk/global-milsatcom

Next week Boeing will be sponsoring Global MilSatCom 2015, Europe’s largest Satellite event. Dan Hart the Vice President from Boeing’s Defence & Space Group will be presenting on hosted payloads as an affordable entry-level investment! https://www.smi-online.co.uk/defence/uk/global-milsatcom

Raytheon will be sponsoring Europe's largest Satellite event next week, Global Milsatcom providing an insight into future Milsatcom Missons. Looks to be an interesting presentation from the Director of Business Development and Strategy! https://www.smi-online.co.uk/defence/uk/global-milsatcom

Ms. Powers will discuss NW Bio’s DCVax® platform technology at SMi's Cancer Vaccines Conference in London in around 3 weeks. Should be an insightful update!

Attendees of the conference will also be invited to join a drinks reception hosted by Northwest Biotherapeutics later that evening on 16th SEPT.

Cancer Vaccines 2015, London Uk